A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus

A critical aspect of the treatment of most patients with type 2 diabetes mellitus (T2DM) is the initiation (and subsequent intensification) of insulin therapy when lifestyle interventions and oral anti-hyperglycaemic drugs fail to maintain or improve glycaemic control. There are several insulin trea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina V. Shestakova, Svetlana V. Elizarova, Abdul Jabbar
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	type 2 diabetes mellitus humalog insulin lispro premixed insulin analog initiation intensification glycated hemoglobin efficacy safety Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/72ce33b77d6449dd98806bc75c8fa576
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72ce33b77d6449dd98806bc75c8fa576
record_format	dspace
spelling	oai:doaj.org-article:72ce33b77d6449dd98806bc75c8fa5762021-11-14T09:00:20ZA review of insulin lispro for the treatment of patients with type 2 diabetes mellitus2072-03512072-037810.14341/DM2003429-34https://doaj.org/article/72ce33b77d6449dd98806bc75c8fa5762016-07-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7595https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378A critical aspect of the treatment of most patients with type 2 diabetes mellitus (T2DM) is the initiation (and subsequent intensification) of insulin therapy when lifestyle interventions and oral anti-hyperglycaemic drugs fail to maintain or improve glycaemic control. There are several insulin treatment options available, including basal insulin, basal-bolus insulin and premixed insulin. Each of these options has advantages and disadvantages. The insulin lispro premixed insulin analogues, mix 25 (25% insulin lisproand 75% insulin lispro protamine suspension) and mix 50 (50% insulin lispro and 50% insulin lispro protamine suspension), which include intermediate- and rapid-acting components, were recently added to Russia’s national drug reimbursement program, increasing the treatment options for patients with T2DM. The aim of this review is to provide Russian physicians with current information on the efficacy and safety of insulin lispro, with a focus on insulin lispro mixtures, for the treatment of T2DM.Marina V. ShestakovaSvetlana V. ElizarovaAbdul JabbarEndocrinology Research Centrearticletype 2 diabetes mellitushumaloginsulin lispropremixed insulin analoginitiationintensificationglycated hemoglobinefficacysafetyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 3, Pp 242-250 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus humalog insulin lispro premixed insulin analog initiation intensification glycated hemoglobin efficacy safety Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus humalog insulin lispro premixed insulin analog initiation intensification glycated hemoglobin efficacy safety Nutritional diseases. Deficiency diseases RC620-627 Marina V. Shestakova Svetlana V. Elizarova Abdul Jabbar A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
description	A critical aspect of the treatment of most patients with type 2 diabetes mellitus (T2DM) is the initiation (and subsequent intensification) of insulin therapy when lifestyle interventions and oral anti-hyperglycaemic drugs fail to maintain or improve glycaemic control. There are several insulin treatment options available, including basal insulin, basal-bolus insulin and premixed insulin. Each of these options has advantages and disadvantages. The insulin lispro premixed insulin analogues, mix 25 (25% insulin lisproand 75% insulin lispro protamine suspension) and mix 50 (50% insulin lispro and 50% insulin lispro protamine suspension), which include intermediate- and rapid-acting components, were recently added to Russia’s national drug reimbursement program, increasing the treatment options for patients with T2DM. The aim of this review is to provide Russian physicians with current information on the efficacy and safety of insulin lispro, with a focus on insulin lispro mixtures, for the treatment of T2DM.
format	article
author	Marina V. Shestakova Svetlana V. Elizarova Abdul Jabbar
author_facet	Marina V. Shestakova Svetlana V. Elizarova Abdul Jabbar
author_sort	Marina V. Shestakova
title	A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_short	A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_full	A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_fullStr	A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_full_unstemmed	A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_sort	review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/72ce33b77d6449dd98806bc75c8fa576
work_keys_str_mv	AT marinavshestakova areviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus AT svetlanavelizarova areviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus AT abduljabbar areviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus AT marinavshestakova reviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus AT svetlanavelizarova reviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus AT abduljabbar reviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus
_version_	1718429538561556480

A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus

Ejemplares similares